An update on PARP inhibitors for the treatment of cancer

OncoTargets and Therapy
Sarah Benafif, Marcia Hall

Abstract

The development of poly (adenosine diphosphate [ADP]) ribose polymerase (PARP) inhibitors (PARPi) has progressed greatly over the last few years and has shown encouraging results in the BRCA1/2 mutation-related cancers. This article attempts to summarize the rationale and theory behind PARPi, the clinical trials already reported, as well as ongoing studies designed to determine the role of PARPi in patients with and without germline mutations of BRCA genes. Future plans for PARPi both as monotherapy and in combination with standard cytotoxics, other biological agents, and as radiosensitizers are also covered. The widening scope of PARPi adds another important targeted agent to the growing list of molecular inhibitors; future and ongoing trials will identify the most effective role for PARPi, including for patients other than BRCA germline mutation carriers.

Citations

Dec 15, 2015·European Journal of Medical Genetics·Karel SvojgrJan Stary
Dec 26, 2017·Frontiers in Immunology·Hassan SadozaiMirjam Schenk
Jul 29, 2017·Journal of Cell Science·Douglas R MackayKatharine S Ullman
Dec 20, 2017·Oncotarget·Zhenzhen Wu, Yuming Wang
Oct 28, 2016·Oncotarget·Clayton A SmithMichael L Freeman
May 26, 2017·Current Treatment Options in Oncology·Praveen Ramakrishnan GeethakumariWm Kevin Kelly
Jun 1, 2017·Hereditary Cancer in Clinical Practice·M DigennaroA V Paradiso
Aug 28, 2021·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Elisabetta GabanoMauro Ravera

❮ Previous
Next ❯

Methods Mentioned

BETA
biopsies
xenograft

Clinical Trials Mentioned

NCT01847274
NCT01844986
NCT01874353
NCT01891344
NCT02032277
NCT01972217
NCT02042378
NCT02184195
NCT01460888
NCT01908478

Related Concepts

Related Feeds

Breast Cancer: BRCA1 & BRCA2

Mutations involving BRCA1, found on chromosome 17, and BRCA2, found on chromosome 13, increase the risk for specific cancers, such as breast cancer. Discover the last research on breast cancer BRCA1 and BRCA2 here.